Insmed Inc Dossier
Qualitative Analysis
Business overview
Insmed Incorporated (NASDAQ: INSM) is a global biopharmaceutical company dedicated to developing and commercializing therapies for patients facing serious and rare diseases. The company's commercial portfolio is anchored by two key approved respiratory products: ARIKAYCE (amikacin liposome inhalation suspension), the first and only FDA-approved therapy for refractory Mycobacterium avium complex (MAC) lung disease, and BRINSUPRI (brensocatib), a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor approved for the treatment of non-cystic fibrosis bronchiectasis (NCFB). Insmed is also advancing a robust clinical pipeline, most notably treprostinil palmitil inhalation powder (TPIP), which is in late-stage development for pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD).
Research as of 29 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Driving the commercial launch of BRINSUPRI (brensocatib) in the U.S. for non-cystic fibrosis bronchiectasis (NCFB) and preparing for international launches in the EU, UK, and Japan.
Expected impact: Targeting at least $1 billion in BRINSUPRI revenues for full-year 2026, establishing Insmed as a commercial-stage leader in the respiratory space.
Advancing Treprostinil Palmitil Inhalation Powder (TPIP) through Phase 3 clinical trials for Pulmonary Arterial Hypertension (PAH) and preparing to initiate Phase 3 trials in progressive pulmonary fibrosis (PPF) and idiopathic pulmonary fibrosis (IPF).
Expected impact: Establishes a robust, multi-indication late-stage pipeline to drive long-term growth beyond the current commercial portfolio.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of global rights to OpSCF (renamed INS1148), a Phase 2-ready monoclonal antibody targeting a specific isoform of Stem Cell Factor (SCF248) to address respiratory, immunological, and inflammatory diseases.
Financial impact: Upfront payment of $40.0 million. Opsidio shareholders are eligible for up to $382 million in contingent milestone payments and low-to-mid single-digit royalties on net sales.
Acquisition of Adrestia's synthetic rescue platform to identify drug targets for genetic diseases, establishing a UK Innovation Center to scale up target discovery.
Financial impact: Initial purchase price of $72.4 million paid in common stock. Former shareholders are eligible for up to $326.5 million in contingent milestone payments and low single-digit royalties.
Strategic Partnerships
Collaborating on an interventional study for brensocatib in bronchiectasis to generate real-world evidence and support clinical adoption in Europe.
Terms: Terms not publicly disclosed.
A multi-project discovery collaboration focused on synthetic rescue targets, inherited from the Adrestia Therapeutics acquisition, which continues to be active under Insmed.
Terms: Terms not publicly disclosed.